论文部分内容阅读
用ＥＬＩＳＡ法测定６８例恶性血液病患者血清可溶性４８ｋＤ跨膜糖蛋白（ｓＦａｓ）水平，用免疫组织化学ＳＡＢＣ法检测其中４６例急性白血病患者骨髓单个核细胞膜Ｆａｓ（ｍＦａｓ）阳性表达细胞数。以患者不同病期及其他临床资料分组，比较各组ｓＦａｓ水平，并对５例急性淋巴细胞白血病（ＡＬＬ）患者进行治疗前后的ｓＦａｓ随访。结果显示，ＡＬＬ组和Ｈｏｄｇｋｉｎ’ｓ淋巴瘤组血清ｓＦａｓ高于正常对照组，且与疾病的发展和病期可能相关。提示ｓＦａｓ可作为临床监测和判断预后的有效指标。急性非淋巴细胞白血病患者（ＡＮＬＬ）血清ｓＦａｓ水平与正常对照差异无显著性。
Serum levels of soluble 48kD transmembrane glycoprotein (sFas) in 68 patients with hematological malignancies were determined by ELISA. Fas (mFas)-positive cells in the bone marrow mononuclear cell membrane were detected in 46 patients with acute leukemia by immunohistochemical SABC method. Patients were divided into different periods and other clinical data to compare the levels of sFas in each group. Five patients with acute lymphoblastic leukemia (ALL) were followed up for sFas before and after treatment. The results showed that the serum sFas in the ALL group and Hodgkin’s lymphoma group was higher than in the normal control group and may be related to the development of the disease and the stage of the disease. It is suggested that sFas can be used as an effective indicator for clinical monitoring and prognosis. Serum sFas levels in patients with acute nonlymphocytic leukemia (ANLL) were not significantly different from those in normal controls.